SCHEMBL6178632

SCHEMBL6178632

COC(=O)C=CCc1ccccc1O[Si](C(C)C)(C(C)C)C(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.41
RAB9A P51151 1/20 0.41
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KDM4E B2RXH2 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NFE2L2 Q16236 1/20 0.35
TSHR P16473 1/20 0.34
ADRB2 P07550 2/20 0.33
ADRB1 P08588 2/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
HTR1A P08908 1/20 0.33
ADRB3 P13945 1/20 0.33
ADRA2C P18825 1/20 0.33
SLC6A2 P23975 1/20 0.33
BDKRB2 P30411 1/20 0.33
SLC6A4 P31645 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6178629 0.76 ALDH1A1 (0.34) POLBRAB9AHTTALDH1A1KDM4E
SCHEMBL7987606 0.75 PTGER4 (0.49) POLBRAB9AHPGDALDH1A1KDM4E
SCHEMBL7987601 0.75 PTGER4 (0.49) POLBRAB9AHPGDALDH1A1KDM4E
SCHEMBL18427869 0.74 TTR (0.45) POLBRAB9AHPGDALDH1A1KDM4E
SCHEMBL17193943 0.74 TTR (0.45) POLBRAB9AHPGDALDH1A1KDM4E
SCHEMBL9843615 0.74 ADRA2C (0.52) ALDH1A1KDM4ETSHRADRB2ADRB1
SCHEMBL15540228 0.73 RAB9A (0.45) POLBRAB9AHTTALDH1A1KMT2A
SCHEMBL15540231 0.73 RAB9A (0.45) POLBRAB9AHTTALDH1A1KMT2A
SCHEMBL27580542 0.73 ALDH1A1 (0.44) POLBRAB9AHPGDALDH1A1KDM4E
SCHEMBL31281851 0.72 SLC6A2 (0.38) HPGDHTTALDH1A1KDM4EHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1061921-A4 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2005-03-30 EP disclosed
US-20020147334-A1 Vitronectin Receptor Antagonists SMITHKLINE BEECHAM CORPORATION 2002-10-10 US disclosed
EP-1061921-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-27 EP disclosed
WO-1999045927-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147334-A1 Vitronectin Receptor Antagonists ADGRF1, FN1, CALCR POLB 4120/4885RAB9A 2387/4885HPGD 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.